Sugitachi A, Kawahara T, Kido T, Shindoh T, Sakamoto I
Dept. of Surgery, Osaka National Hospital, Japan.
Gan To Kagaku Ryoho. 1990 Aug;17(8 Pt 2):1583-7.
We carried out a new loco-regional cancer chemotherapy for serious patients with malignant pleural effusion, in an attempt to prevent the recurrence of effusion. After removing pleural effusion, fibrinogen solution, anticancer agent and our newly devised compound drug, "G.T.XIII" were intrapleurally instilled to enhance an anticancer fibrin membrane. This pleurodesis was called "Bio-Adhesio-Chemo (BAC) therapy". Some 39 BAC therapies were carried out for 34 patients. There were 32 cases evaluable; 29 resulted in PR, and three were NC. Improvement of P.S. was observed in 77% (30/39). Aggravation of P.S. was nil. Sixteen patients were discharged after showing favorable improvement. Toxic effects with the therapy were rather mild. Such results were attributed to the biomechanism of both the adhesive and oncolytic effects of the fibrin membrane enhanced with BAC therapy. Immunological studies suggested that the fibrin membrane also worked as BRM in the pleural cavity. Our own BAC therapy showed a great potential in improving the QOL of patients with malignant pleural effusion.
我们对重症恶性胸腔积液患者开展了一种新的局部区域癌症化疗，以防止胸腔积液复发。在抽去胸腔积液后，向胸腔内注入纤维蛋白原溶液、抗癌剂以及我们新研制的复合药物“G.T.XIII”，以增强抗癌纤维蛋白膜。这种胸膜固定术被称为“生物黏附化疗（BAC）疗法”。我们对34例患者进行了约39次BAC疗法。其中32例可评估；29例达到部分缓解（PR），3例为疾病稳定（NC）。77%（30/39）的患者体力状况（P.S.）得到改善。未出现P.S.恶化情况。16例患者在病情明显改善后出院。该疗法的毒性作用相当轻微。这些结果归因于BAC疗法增强的纤维蛋白膜的黏附及溶瘤作用的生物机制。免疫学研究表明，纤维蛋白膜在胸腔内也起到生物反应调节剂（BRM）的作用。我们的BAC疗法在改善恶性胸腔积液患者的生活质量方面显示出巨大潜力。
